{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:10:06Z","timestamp":1789420206065,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40744-021-00421-w","type":"journal-article","created":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T05:02:30Z","timestamp":1641618150000},"page":"555-563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effect of Leflunomide on Pegloticase Response Rate in Patients with Uncontrolled Gout: A Retrospective Study"],"prefix":"10.1007","volume":"9","author":[{"given":"Karim Richard","family":"Masri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissa","family":"Padnick-Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Winterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7521-241X","authenticated-orcid":false,"given":"Brian","family":"LaMoreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,8]]},"reference":[{"key":"421_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jama.2011.1617","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306:711\u201320.","journal-title":"JAMA"},{"key":"421_CR2","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1186\/ar4497","volume":"16","author":"PE Lipsky","year":"2014","unstructured":"Lipsky PE, Calabrese LH, Kavanaugh A, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16:R60.","journal-title":"Arthritis Res Ther"},{"key":"421_CR3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13075-018-1782-x","volume":"20","author":"BF Mandell","year":"2018","unstructured":"Mandell BF, Yeo AE, Lipsky PE. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase. Arthritis Res Ther. 2018;20:286.","journal-title":"Arthritis Res Ther"},{"key":"421_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1477-7525-10-117","volume":"10","author":"PP Khanna","year":"2012","unstructured":"Khanna PP, Nuki G, Bardin T, et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey. Health Qual Life Outcomes. 2012;10:117.","journal-title":"Health Qual Life Outcomes"},{"key":"421_CR5","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s10067-017-3963-4","volume":"37","author":"KA Lee","year":"2018","unstructured":"Lee KA, Ryu SR, Park SJ, Kim HR, Lee SH. Assessment of cardiovascular risk profile based on measurement of tophus volume in patients with gout. Clin Rheumatol. 2018;37:1351\u20138.","journal-title":"Clin Rheumatol"},{"key":"421_CR6","doi-asserted-by":"publisher","unstructured":"Botson JK, Peterson J. Pretreatment and coadministration with methotrexate improved durability of pegloticase response: an observational, proof-of-concept case series. J Clin Rheumatol. 2020 [Epub ahead of print]. https:\/\/doi.org\/10.1097\/RHU.0000000000001639.","DOI":"10.1097\/RHU.0000000000001639"},{"key":"421_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3899\/jrheum.200460","volume":"48","author":"JK Botson","year":"2021","unstructured":"Botson JK, Tesser JRP, Bennett R, et al. Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR). J Rheumatol. 2021;48:767\u201374.","journal-title":"J Rheumatol"},{"key":"421_CR8","first-page":"238","volume":"14","author":"MY Bessen","year":"2019","unstructured":"Bessen MY, Bessen SY, Yung CM. Concomitant immunosuppressant use with pegloticase in patients with tophaceous gout - a case series. Int J Clin Rheumatol. 2019;14:238\u201345.","journal-title":"Int J Clin Rheumatol"},{"key":"421_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.semarthrit.2018.11.006","volume":"49","author":"SY Bessen","year":"2019","unstructured":"Bessen SY, Bessen MY, Yung CM. Recapture and improved outcome of pegloticase response with methotrexate\u2014a report of two cases and review of the literature. Semin Arthritis Rheum. 2019;49:56\u201361.","journal-title":"Semin Arthritis Rheum"},{"key":"421_CR10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40744-020-00222-7","volume":"7","author":"JA Albert","year":"2020","unstructured":"Albert JA, Hosey T, LaMoreaux B. Increased efficacy and tolerability of pegloticase in patients with uncontrolled gout co-treated with methotrexate: a retrospective study. Rheumatol Ther. 2020;7:639\u201348.","journal-title":"Rheumatol Ther"},{"key":"421_CR11","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/art.41731","volume":"73","author":"PP Khanna","year":"2021","unstructured":"Khanna PP, Khanna D, Cutter G, et al. Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2021;73:1523\u201332.","journal-title":"Arthritis Rheumatol"},{"key":"421_CR12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1136\/annrheumdis-2020-eular.4642","volume":"79","author":"H Rainey","year":"2020","unstructured":"Rainey H, Baraf HSB, Yeo A, Lipsky P. Companion immunosuppression with azathioprine increases the frequency of persistent responsiveness to pegloticase in patients with chronic refractory gout. Ann Rheumatic Dis. 2020;79:438.","journal-title":"Ann Rheumatic Dis"},{"key":"421_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.semarthrit.2021.01.005","volume":"51","author":"RT Keenan","year":"2021","unstructured":"Keenan RT, Botson JK, Masri KR, et al. The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review. Semin Arthritis Rheum. 2021;51:347\u201352.","journal-title":"Semin Arthritis Rheum"},{"key":"421_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1053\/sarh.2000.16641","volume":"30","author":"MH Schiff","year":"2000","unstructured":"Schiff MH, Whelton A. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2000;30:196\u2013208.","journal-title":"Semin Arthritis Rheum"},{"key":"421_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40744-020-00260-1","volume":"8","author":"M Francis-Sedlak","year":"2021","unstructured":"Francis-Sedlak M, LaMoreaux B, Padnick-Silver L, Holt RJ, Bello AE. Characteristics, comorbidities, and potential consequences of uncontrolled gout: an insurance-claims database study. Rheumatol Ther. 2021;8:183\u201397.","journal-title":"Rheumatol Ther"},{"key":"421_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12882-019-1274-5","volume":"20","author":"JA Singh","year":"2019","unstructured":"Singh JA, Cleveland JD. Gout is associated with a higher risk of chronic renal disease in older adults: a retrospective cohort study of U.S. Medicare population. BMC Nephrol. 2019;20:93.","journal-title":"BMC Nephrol."},{"key":"421_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","volume":"17","author":"MJ Roughley","year":"2015","unstructured":"Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17:90.","journal-title":"Arthritis Res Ther"},{"key":"421_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","volume":"353","author":"JS Smolen","year":"1999","unstructured":"Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared to placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, ransomised, multicentre trial. Lancet. 1999;353:259\u201366.","journal-title":"Lancet"},{"key":"421_CR19","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","volume":"159","author":"V Strand","year":"1999","unstructured":"Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med. 1999;159:2542\u201350.","journal-title":"Arch Intern Med."},{"key":"421_CR20","unstructured":"ARAVA\u00ae (leflunomide) [package insert]. Sanofi-Aventis U.S. LLC, Bridgewater, NJ; February 2016. https:\/\/products.sanofi.us\/arava\/Arava.pdf. Accessed December 2, 2021."},{"key":"421_CR21","unstructured":"KRYSTEXXA\u00ae (pegloticase) [package insert]. Horizon Therapeutics Ireland DAC, Dublin, Ireland; March 2021. https:\/\/www.hzndocs.com\/KRYSTEXXA-Prescribing-Information.pdf. Accessed December 2, 2021."},{"key":"421_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40744-019-0151-9","volume":"6","author":"RT Keenan","year":"2019","unstructured":"Keenan RT, Baraf HS, LaMoreaux B. Use of pre-infusion serum uric acid levels as a biomarker for infusion reaction risk in patients on pegloticase. Rheumatol Ther. 2019;6:299\u2013304.","journal-title":"Rheumatol Ther"},{"key":"421_CR23","doi-asserted-by":"crossref","first-page":"852","DOI":"10.55563\/clinexprheumatol\/jhpymv","volume":"39","author":"G Kimyon","year":"2021","unstructured":"Kimyon G, Kalyoncu U, Kiraz S, et al. Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data. Clin Exp Rheumatol. 2021;39:852\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"421_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123392","volume":"10","author":"J Narv\u00e1ez","year":"2015","unstructured":"Narv\u00e1ez J, D\u00edaz-Torn\u00e9 C, Magallares B, et al. Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. PloS One. 2015;10: e0123392.","journal-title":"PloS One"},{"key":"421_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1136\/ard.2007.085696","volume":"68","author":"A Finckh","year":"2009","unstructured":"Finckh A, Dehler S, Gabay C. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2009;68:33\u20139.","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00421-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-021-00421-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00421-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T08:40:33Z","timestamp":1674376833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-021-00421-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,8]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["421"],"URL":"https:\/\/doi.org\/10.1007\/s40744-021-00421-w","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,8]]},"assertion":[{"value":"16 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}